The function of steroid receptor coactivator-1 in normal tissues and cancer

International Journal of Biological Sciences

Volumn 8, Issue 4, 2012, Pages 470-485

  Walsh, Claire A ^a   Qin, Li ^b   Tien, Jean Ching Yi ^b   Young, Leonie S ^a   Xu, Jianming ^b,c  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c SOUTHWEST MEDICAL UNIVERSITY   (China)

Author keywords

Cancer; Coactivator; Development; Nuclear receptor; SRC 1; Transcription

Indexed keywords

CELL RECEPTOR; STEROID RECEPTOR COACTIVATOR 1;

ANIMAL; GENETICS; HUMAN; METABOLISM; NEOPLASM; REVIEW;

ANIMALS; HUMANS; NEOPLASMS; NUCLEAR RECEPTOR COACTIVATOR 1; RECEPTORS, CYTOPLASMIC AND NUCLEAR;

EID: 84859055574     PISSN: 14492288     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijbs.4125     Document Type: Review

References (121)

1. Spelsberg TC, Steggles AW, O'Malley BW. Progesterone-binding Components of Chick Oviduct. J Biol Chem. 1971; 246: 4188-97.
2. York B, O'Malley BW. Steroid Receptor Coactivator (SRC) Family: Masters of Systems Biology. J Biol Chem. 2010; 285: 38743-50.
3. Klein-Hitpass L, Tsai SY, Weigel NL, et al. The progesterone receptor stimulates cell-free transcription by enhancing the formation of a stable preinitiation complex. Cell. 1990; 60: 247-57.
4. Kim J, Stallcup M. P160 Coactivators: Critical Mediators of Transcriptional Activation by Nuclear Receptors. Singapore: World Scientific Publishing Co Pte Ltd. 2008.
5. Meyer M-E, Gronemeyer H, Turcotte B, et al. Steroid hormone receptors compete for factors that mediate their enhancer function. Cell. 1989; 57: 433-42.
6. Onate S, Tsai S, Tsai MJ, et al. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science. 1995; 24: 1354-7.
7. Wang J-C, Stafford JM, Granner DK. SRC-1 and GRIP1 Coactivate Transcription with Hepatocyte Nuclear Factor 4. J Biol Chem. 1998; 273: 30847-50.
8. Zhu Y, Qi C, Calandra C, et al. Cloning and identification of mouse steroid receptor coactivator-1 (mSRC-1), as a coactivator of peroxisome proliferator-activated receptor gamma. Gene Expr. 1996; 6: 185-95.
9. Ding XF, Anderson CM, Ma H, et al. Nuclear receptor-binding sites of coactivators glucocorticoid receptor interacting protein 1 (GRIP1) and steroid receptor coactivator 1 (SRC-1): multiple motifs with different binding specificities. Mol Endocrinol. 1998; 12: 302-13.
10. Zhou G, Cummings R, Li Y, et al. Nuclear receptors have distinct affinities for coactivators: characterization by fluorescence resonance energy transfer. Mol Endocrinol. 1998; 12: 1594-604.
11. Lee S-K, Kim H-J, Na S-Y, et al. Steroid Receptor Coactivator-1 Coactivates Activating Protein-1-mediated Transactivations through Interaction with the c-Jun and c-Fos Subunits. J Biol Chem. 1998; 273: 16651-4.
12. Kim H-J, Kim JH, Lee JW. Steroid Receptor Coactivator-1 Interacts with Serum Response Factor and Coactivates Serum Response Element-mediated Transactivations. J Biol Chem. 1998; 273: 28564-7.
13. Na S-Y, Lee S-K, Han S-J, et al. Steroid Receptor Coactivator-1 Interacts with the p50 Subunit and Coactivates Nuclear Factor κB-mediated Transactivations. J Biol Chem. 1998; 273: 10831-4.
14. Myers E, Hill ADK, Kelly G, et al. Associations and Interactions between Ets-1 and Ets-2 and Coregulatory Proteins, SRC-1, AIB1, and NCoR in Breast Cancer. Clin Cancer Res. 2005; 11: 2111-22.
15. McIlroy M, McCartan D, Early S, et al. Interaction of Developmental Transcription Factor HOXC11 with Steroid Receptor Coactivator SRC-1 Mediates Resistance to Endocrine Therapy in Breast Cancer. Cancer Res. 2010; 70: 1585-94.
16. Qin L, Chen X, Wu Y, et al. Steroid Receptor Coactivator-1 Upregulates Integrin α5 Expression to Promote Breast Cancer Cell Adhesion and Migration. Cancer Res. 2011; 71: 1742-51.
17. Qin L, Liu Z, Chen H, et al. The Steroid Receptor Coactivator-1 Regulates Twist Expression and Promotes Breast Cancer Metastasis. Cancer Res. 2009; 69: 3819-27.
18. Hong H, Kohli K, Trivedi A, et al. GRIP1, a novel mouse protein that serves as a transcriptional coactivator in yeast for the hormone binding domains of steroid receptors. Proc Natl Acad Sci U S A. 1996; 93: 4948-52.
19. Torchia J, Rose DW, Inostroza J, et al. The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function. Nature. 1997; 387: 677-84.
20. Lonard DM, O'Malley BW. Nuclear Receptor Coregulators: Judges, Juries, and Executioners of Cellular Regulation. Mol Cell. 2007; 27: 691-700.
21. Zhang H, Yi X, Sun X, et al. Differential gene regulation by the SRC family of coactivators. Genes Dev. 2004; 18: 1753-65.
22. Kim JH, Li H, Stallcup MR. CoCoA, a Nuclear Receptor Coactivator which Acts through an N-Terminal Activation Domain of p160 Coactivators. Mol cell. 2003; 12: 1537-49.
23. Liu Z, Wong J, Tsai SY, et al. Sequential recruitment of steroid receptor coactivator-1 (SRC-1) and p300 enhances progesterone receptor-dependent initiation and reinitiation of transcription from chromatin. Proc Natl Acad Sci U S A. 2001; 98: 12426-31.
24. Li C, Wu R-C, Amazit L, et al. Specific Amino Acid Residues in the Basic Helix-Loop-Helix Domain of SRC-3 Are Essential for Its Nuclear Localization and Proteasome-Dependent Turnover. Mol Cell Biol. 2007; 27: 1296-308.
25. Chang C-y, Norris JD, Grøn H, et al. Dissection of the LXXLL Nuclear Receptor-Coactivator Interaction Motif Using Combinatorial Peptide Libraries: Discovery of Peptide Antagonists of Estrogen Receptors α and β. Mol Cell Biol. 1999; 19: 8226-39.
26. Heery DM, Kalkhoven E, Hoare S, et al. A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature. 1997; 387: 733-6.
27. Lanz RB, Lonard DM, O'Malley BW. Nuclear Receptor Coregulators in Human Diseases. Singapore: World Scientific Publishing Co Pte Ltd. 2008.
28. Coulthard VH, Matsuda S, Heery DM. An Extended LXXLL Motif Sequence Determines the Nuclear Receptor Binding Specificity of TRAP220. J Biol Chem. 2003; 278: 10942-51.
29. Heery DM, Hoare S, Hussain S, et al. Core LXXLL motif sequences in CREB-binding protein, SRC1, and RIP140 define affinity and selectivity for steroid and retinoid receptors. J Biol Chem. 2001; 276: 6695-702.
30. Shiau AK, Barstad D, Loria PM, et al. The Structural Basis of Estrogen Receptor/Coactivator Recognition and the Antagonism of This Interaction by Tamoxifen. Cell. 1998; 95: 927-37.
31. Bourguet W, Germain P, Gronemeyer H. Nuclear receptor ligand-binding domains: three-dimensional structures, molecular interactions and pharmacological implications. Trends Pharmacol Sci. 2000; 21: 381-8.
32. Kraus WL, Manning ET, Kadonaga JT. Biochemical Analysis of Distinct Activation Functions in p300 That Enhance Transcription Initiation with Chromatin Templates. Mol Cell Biol. 1999; 19: 8123-35.
33. Chen H, Lin RJ, Schiltz RL, et al. Nuclear Receptor Coactivator ACTR Is a Novel Histone Acetyltransferase and Forms a Multimeric Activation Complex with P/CAF and CBP/p300. Cell. 1997; 90: 569-80.
34. Spencer TE, Jenster G, Burcin MM, et al. Steroid receptor coactivator-1 is a histone acetyltransferase. Nature. 1997; 389: 194-8.
35. Yang X-J, Ogryzko VV, Nishikawa J-i, et al. A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A. Nature. 1996; 382: 319-24.
36. Voegel J, Heine M, Zechel C, et al. TIF2, a 160 kDa transcriptional mediator for the ligand-dependent activation function AF-2 of nuclear receptors. EMBO J. 1996; 15: 3667-75.
37. Onate SA, Boonyaratanakornkit V, Spencer TE, et al. The Steroid Receptor Coactivator-1 Contains Multiple Receptor Interacting and Activation Domains That Cooperatively Enhance the Activation Function 1 (AF1) and AF2 Domains of Steroid Receptors. J Biol Chem. 1998; 273: 12101-8.
38. Voegel JJ, Heine MJS, Tini M, et al. The coactivator TIF2 contains three nuclear receptor-binding motifs and mediates transactivation through CBP binding-dependent and-independent pathways. EMBO J. 1998; 17: 507-19.
39. Li J, O'Malley BW, Wong J. p300 Requires Its Histone Acetyltransferase Activity and SRC-1 Interaction Domain To Facilitate Thyroid Hormone Receptor Activation in Chromatin. Mol Cell Biol. 2000; 20: 2031-42.
40. Nakajima T, Uchida C, Anderson SF, et al. RNA Helicase A Mediates Association of CBP with RNA Polymerase II. Cell. 1997; 90: 1107-12.
41. Koh SS, Chen D, Lee Y-H, et al. Synergistic Enhancement of Nuclear Receptor Function by p160 Coactivators and Two Coactivators with Protein Methyltransferase Activities. J Biol Chem. 2001; 276: 1089-98.
42. Daujat S, Bauer U-M, Shah V, et al. Crosstalk between CARM1 Methylation and CBP Acetylation on Histone H3. Curr Biol. 2002; 12: 2090-7.
43. Lee DY, Teyssier C, Strahl BD, et al. Role of Protein Methylation in Regulation of Transcription. Endocr Rev. 2005; 26: 147-70.
44. Wang H, Huang Z, Xia L, et al. Methylation of histone H4 at arginine 3 facilitating transcriptional activation by nuclear hormone receptor. Science. 2001; 293: 853-7.
45. Johnson AB, O'Malley BW. Steroid receptor coactivators 1, 2, and 3: Critical regulators of nuclear receptor activity and steroid receptor modulator (SRM)-based cancer therapy. Mol Cell Endocrinol. 2012; 348: 430-9.
46. Belandia B, Orford RL, Hurst HC, et al. Targeting of SWI/SNF chromatin remodelling complexes to estrogen-responsive genes. EMBO J. 2002; 21: 4094-103.
47. Xu J, Wu R-C, O'Malley BW. Normal and cancer-related functions of the p160 steroid receptor co-activator (SRC) family. Nat Rev Cancer. 2009; 9: 615-30.
48. Shah YM, Rowan BG. The Src Kinase Pathway Promotes Tamoxifen Agonist Action in Ishikawa Endometrial Cells through Phosphorylation-Dependent Stabilization of Estrogen Receptor α Promoter Interaction and Elevated Steroid Receptor Coactivator 1 Activity. Mol Endocrinol. 2005; 19: 732-48.
49. Rowan BG, Weigel NL, O'Malley BW. Phosphorylation of Steroid Receptor Coactivator-1. J Biol Chem. 2000; 275: 4475-83.
50. Coleman KM, Dutertre M, El-Gharbawy A, et al. Mechanistic Differences in the Activation of Estrogen Receptor-α (ERα)-and ERβ-dependent Gene Expression by cAMP Signaling Pathway(s). J Biol Chem. 2003; 278: 12834-45.
51. Wu R-C, Feng Q, Lonard DM, et al. SRC-3 Coactivator Functional Lifetime Is Regulated by a Phospho-Dependent Ubiquitin Time Clock. Cell. 2007; 129: 1125-40.
52. Hartmaier RJ, Richter AS, Gillihan RM, et al. A SNP in Steroid Receptor Coactivator-1 Disrupts a GSK3beta Phosphorylation Site and Is Associated with Altered Tamoxifen Response in Bone. Mol Endocrinol. 2012; 26: 220-7.
53. O'Malley BW. The "Fourth Dimension" of Gene Transcription. Mol Endocrinol. 2009; 23: 587-9.
54. Xu J, Qiu Y, De Mayo FJ, et al. Partial hormone resistance in mice with disruption of the steroid receptor coactivator-1 (SRC-1) gene. Science. 1998; 279: 1922-5.
55. Han SJ, De Mayo FJ, Xu J, et al. Steroid receptor coactivator (SRC)-1 and SRC-3 differentially modulate tissue-specific activation functions of the progesterone receptor. Mol Endocrinol. 2006; 20: 45-55.
56. Jeong JW, Lee HS, Lee KY, et al. Mig-6 modulates uterine steroid hormone responsiveness and exhibits altered expression in endometrial disease. Proc Natl Acad Sci U S A. 2009; 106: 8677-82.
57. Shiozawa T, Shih HC, Miyamoto T, et al. Cyclic changes in the expression of steroid receptor coactivators and corepressors in the normal human endometrium. J Clin Endocrinol Metab. 2003; 88: 871-8.
58. Wieser F, Schneeberger C, Hudelist G, et al. Endometrial nuclear receptor co-factors SRC-1 and N-CoR are increased in human endometrium during menstruation. Mol Hum Reprod. 2002; 8: 644-50.
59. Hong CY, Suh JH, Kim K, et al. Modulation of androgen receptor transactivation by the SWI3-related gene product (SRG3) in multiple ways. Mol Cell Biol. 2005; 25: 4841-52.
60. Topper YJ, Freeman CS. Multiple hormone interactions in the developmental biology of the mammary gland. Physiol Rev. 1980; 60: 1049-106.
61. Nishihara E, Yoshida-Komiya H, Chan CS, et al. SRC-1 null mice exhibit moderate motor dysfunction and delayed development of cerebellar Purkinje cells. J Neurosci. 2003; 23: 213-22.
62. Weiss RE, Xu J, Ning G, et al. Mice deficient in the steroid receptor co-activator 1 (SRC-1) are resistant to thyroid hormone. EMBO J. 1999; 18: 1900-4.
63. Sadow PM, Koo E, Chassande O, et al. Thyroid hormone receptor-specific interactions with steroid receptor coactivator-1 in the pituitary. Mol Endocrinol. 2003; 17: 882-94.
64. Modder UI, Sanyal A, Kearns AE, et al. Effects of loss of steroid receptor coactivator-1 on the skeletal response to estrogen in mice. Endocrinology. 2004; 145: 913-21.
65. Mödder UI, Sanyal A, Xu J, et al. The skeletal response to estrogen is impaired in female but not in male steroid receptor coactivator (SRC)-1 knock out mice. Bone. 2008; 42: 414-21.
66. Yamada T, Kawano H, Sekine K, et al. SRC-1 is necessary for skeletal responses to sex hormones in both males and females. J Bone Miner Res. 2004; 19: 1452-61.
67. Hartmaier R, Tchatchou S, Richter A, et al. Nuclear receptor coregulator SNP discovery and impact on breast cancer risk. BMC Cancer. 2009; 9: 438.
68. Yuan Y, Xu J. Loss-of-Function Deletion of the Steroid Receptor Coactivator-1 Gene in Mice Reduces Estrogen Effect on the Vascular Injury Response. Arterioscler Thromb Vasc Biol. 2007; 27: 1521-7.
69. Yuan Y, Liao L, Tulis DA, et al. Steroid Receptor Coactivator-3 Is Required for Inhibition of Neointima Formation by Estrogen. Circulation. 2002; 105: 2653-9.
70. 3 Is Required for Placental, Cardiac, and Adipose Tissue Development. Mol Cell. 1999; 4: 585-95.
71. Puigserver P, Adelmant G, Wu Z, et al. Activation of the PPARgamma coactivator-1 through transcription factor docking. Science. 1999; 286: 1368-71.
72. Picard F, Géhin M, Annicotte J-S, et al. SRC-1 and TIF2 Control Energy Balance between White and Brown Adipose Tissues. Cell. 2002; 111: 931-41.
73. Wang Z, Qi C, Krones A, et al. Critical roles of the p160 transcriptional coactivators p/CIP and SRC-1 in energy balance. Cell Metab. 2006; 3: 111-22.
74. Louet J-F, Chopra AR, Sagen JV, et al. The Coactivator SRC-1 Is an Essential Coordinator of Hepatic Glucose Production. Cell Metab. 2010; 12: 606-18.
75. Nedumaran B, Kim GS, Hong S, et al. Orphan nuclear receptor DAX-1 acts as a novel corepressor of liver X receptor alpha and inhibits hepatic lipogenesis. J Biol Chem. 2010; 285: 9221-32.
76. Xu J, Li Q. Review of the in vivo functions of the p160 steroid receptor coactivator family. Mol Endocrinol. 2003; 17: 1681-92.
77. Mark M, Yoshida-Komiya H, Gehin M, et al. Partially redundant functions of SRC-1 and TIF2 in postnatal survival and male reproduction. Proc Natl Acad Sci U S A. 2004; 101: 4453-8.
78. Mukherjee A, Soyal SM, Fernandez-Valdivia R, et al. Steroid receptor coactivator 2 is critical for progesterone-dependent uterine function and mammary morphogenesis in the mouse. Mol Cell Biol. 2006; 26: 6571-83.
79. Chen X, Liu Z, Xu J. The Cooperative Function of Nuclear Receptor Coactivator 1 (NCOA1) and NCOA3 in Placental Development and Embryo Survival. Mol Endocrinol. 2010; 24: 1917-34.
80. Hudelist G, Czerwenka K, Kubista E, et al. Expression of Sex Steroid Receptors and their Co-Factors in Normal and Malignant Breast Tissue: AIB1 is a Carcinoma-Specific Co-Activator. Breast Cancer Res Treat. 2003; 78: 193-204.
81. Fleming FJ, Hill ADK, McDermott EW, et al. Differential Recruitment of Coregulator Proteins Steroid Receptor Coactivator-1 and Silencing Mediator for Retinoid and Thyroid Receptors to the Estrogen Receptor-Estrogen Response Element by β-Estradiol and 4-Hydroxytamoxifen in Human Breast Cancer. J Clin Endocrinol Metab. 2004; 89: 375-83.
82. Wang S, Yuan Y, Liao L, et al. Disruption of the SRC-1 gene in mice suppresses breast cancer metastasis without affecting primary tumor formation. Proc Natl Acad Sci U S A. 2009; 106: 151-6.
83. Leek RD, Lewis CE, Whitehouse R, et al. Association of Macrophage Infiltration with Angiogenesis and Prognosis in Invasive Breast Carcinoma. Cancer Res. 1996; 56: 4625-9.
84. Wyckoff J, Wang W, Lin EY, et al. A Paracrine Loop between Tumor Cells and Macrophages Is Required for Tumor Cell Migration in Mammary Tumors. Cancer Res. 2004; 64: 7022-9.
85. Han J, Crowe D. Steroid receptor coactivator 1 deficiency increases MMTV-neu mediated tumor latency and differentiation specific gene expression, decreases metastasis, and inhibits response to PPAR ligands. BMC Cancer. 2010; 10: 629.
86. Fleming FJ, Myers E, Kelly G, et al. Expression of SRC-1, AIB1, and PEA3 in HER2 mediated endocrine resistant breast cancer; a predictive role for SRC-1. J Clin Pathol. 2004; 57: 1069-74.
87. Al-azawi D, McIlroy M, Kelly G, et al. Ets-2 and p160 proteins collaborate to regulate c-Myc in endocrine resistant breast cancer. Oncogene. 2008; 27: 3021-31.
88. McBryan J, Theissen SM, Byrne C, et al. Metastatic progression with resistance to aromatase inhibitors is driven by the steroid receptor coactivator SRC-1. Cancer Res. 2012; 72: 548-59.
89. Kishimoto H, Wang Z, Bhat-Nakshatri P, et al. The p160 family coactivators regulate breast cancer cell proliferation and invasion through autocrine/paracrine activity of SDF-1α/CXCL12. Carcinogenesis. 2005; 26: 1706-15.
90. Li YM, Pan Y, Wei Y, et al. Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer cell. 2004; 6: 459-69.
91. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest. 2009; 119: 1420-8.
92. Yang J, Mani SA, Donaher JL, et al. Twist, a Master Regulator of Morphogenesis, Plays an Essential Role in Tumor Metastasis. Cell. 2004; 117: 927-39.
93. Hong J, Zhou J, Fu J, et al. Phosphorylation of Serine 68 of Twist1 by MAPKs Stabilizes Twist1 Protein and Promotes Breast Cancer Cell Invasiveness. Cancer Res. 2011; 71: 3980-90.
94. Luo B-H, Carman CV, Springer TA. Structural Basis of Integrin Regulation and Signaling. Annu Rev Immunol. 2007; 25: 619-47.
95. Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 2010; 10: 9-22.
96. Smith CL, Nawaz Z, O'Malley BW. Coactivator and Corepressor Regulation of the Agonist/Antagonist Activity of the Mixed Antiestrogen, 4-Hydroxytamoxifen. Mol Endocrinol. 1997; 11: 657-66.
97. Shang Y, Brown M. Molecular Determinants for the tissue specificty of SERMs. Science. 2002; 295: 2465-8.
98. Romano A, Adriaens M, Kuenen S, et al. Identification of novel ER-α target genes in breast cancer cells: Gene-and cell-selective co-regulator recruitment at target promoters determines the response to 17β-estradiol and tamoxifen. Mol Cell Endocrinol. 2010; 314: 90-100.
99. Hurtado A, Holmes KA, Geistlinger TR, et al. Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen. Nature. 2008; 456: 663-6.
100. Liu Z, Auboeuf D, Wong J, et al. Coactivator/corepressor ratios modulate PR-mediated transcription by the selective receptor modulator RU486. Proc Natl Acad Sci U S A. 2002; 99: 7940-4.
101. Lonard DM, Tsai SY, O'Malley BW. Selective Estrogen Receptor Modulators 4-Hydroxytamoxifen and Raloxifene Impact the Stability and Function of SRC-1 and SRC-3 Coactivator Proteins. Mol Cell Biol. 2004; 24: 14-24.
102. Haugan Moi LL, Hauglid Flågeng M, Gandini S, et al. Effect of Low-Dose Tamoxifen on Steroid Receptor Coactivator 3/Amplified in Breast Cancer 1 in Normal and Malignant Human Breast Tissue. Clin Cancer Res. 2010; 16: 2176-86.
103. Scott D, Parkes A, Ponchel F, et al. Changes in expression of steroid receptors, their downstream target genes, and their associated co-regulators during the sequential acquisition of tamoxifen resistance in vitro. Int J Oncol. 2007; 31: 557-65.
104. Redmond AM, Bane FT, Stafford AT, et al. Coassociation of Estrogen Receptor and p160 Proteins Predicts Resistance to Endocrine Treatment; SRC-1 is an Independent Predictor of Breast Cancer Recurrence. Clin Cancer Res. 2009; 15: 2098-106.
105. Zwart W, Griekspoor A, Berno V, et al. PKA-induced resistance to tamoxifen is associated with an altered orientation of ER[alpha] towards co-activator SRC-1. EMBO J. 2007; 26: 3534-44.
106. Holm C, Rayala S, Jirström K, et al. Association Between Pak1 Expression and Subcellular Localization and Tamoxifen Resistance in Breast Cancer Patients. J Natl Cancer Inst. 2006; 98: 671-80.
107. McCartan D, Bolger J, Fagan A, et al. Global characterization of the SRC-1 transcriptome identifies ADAM22 as an ER-independent mediator of endocrine resistant breast cancer. Cancer Res. 2012; 72: 220-9.
108. Agoulnik IU, Vaid A, Bingman WE, et al. Role of SRC-1 in the Promotion of Prostate Cancer Cell Growth and Tumor Progression. Cancer Res. 2005; 65: 7959-67.
109. Gregory CW, He B, Johnson RT, et al. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res. 2001; 61: 4315-9.
110. Linja MJ, Porkka KP, Kang Z, et al. Expression of androgen receptor coregulators in prostate cancer. Clin Cancer Res. 2004; 10: 1032-40.
111. Maki HE, Waltering KK, Wallen MJ, et al. Screening of genetic and expression alterations of SRC1 gene in prostate cancer. Prostate. 2006; 66: 1391-8.
112. Ueda T, Mawji NR, Bruchovsky N, et al. Ligand-independent Activation of the Androgen Receptor by Interleukin-6 and the Role of Steroid Receptor Coactivator-1 in Prostate Cancer Cells. J Biol Chem. 2002; 277: 38087-94.
113. Tien JC, Zhou S, Xu J. The role of SRC-1 in murine prostate cancinogenesis is nonessential due to a possible compensation of SRC-3/AIB1 overexpression. Int J Biol Sci. 2009; 5: 256-64.
114. Kershah SM, Desouki MM, Koterba KL, et al. Expression of estrogen receptor coregulators in normal and malignant human endometrium. Gynecol Oncol. 2004; 92: 304-13.
115. Uchikawa J, Shiozawa T, Shih HC, et al. Expression of steroid receptor coactivators and corepressors in human endometrial hyperplasia and carcinoma with relevance to steroid receptors and Ki-67 expression. Cancer. 2003; 98: 2207-13.
116. Kavanagh DO, McIlroy M, Myers E, et al. The role of oestrogen receptor α in human thyroid cancer: contributions from coregulatory proteins and the tyrosine kinase receptor HER2. Endocr Relat Cancer. 2010; 17: 255-64.
117. Donato R, Sorci G, Riuzzi F, et al. S100B's double life: Intracellular regulator and extracellular signal. Biochim Biophys Acta. 2009; 1793: 1008-22.
118. Mocellin S, Zavagno G, Nitti D. The prognostic value of serum S100B in patients with cutaneous melanoma: A meta-analysis. Int J Cancer. 2008; 123: 2370-6.
119. deBlacam C, Byrne C, Hughes E, et al. HOXC11-SRC-1 regula-tion of S100beta in cutaneous melanoma: new targets for the kinase inhibitor dasatinib. Br J Cancer. 2011; 105: 118-23.
120. Wang Y, Lonard DM, Yu Y, et al. Small molecule inhibition of the steroid receptor coactivators, SRC-3 and SRC-1. Mol Endo-crinol. 2011; 25: 2041-53.
121. O'Malley BW. Masters of the genome. Nat Rev Mol Cell Biol. 2010; 11: 311.